Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based SciClone Pharmaceuticals has renewed an exclusive agreement with Sanofi to promote four products including Depakine, Stilnox, Tritace and Xatral in China.
Subscribe to our email newsletter
According to the renewed deal, Novamed Pharmaceuticals, a wholly owned subsidiary of SciClone, will promote the products in the region till 31 December 2013 with a possibility of further extension.
SciClone president and chief executive officer Friedhelm Blobel said, "We look forward to continuing to deepen the market penetration and expand the commercial success of these high quality, therapeutically differentiated products in China."
Previously the set of agreements were scheduled to expire between the end of 2012 and 30 June 2013.
Depakine (sodium valproate) is an anti-epileptic drug, Stilnox (zolpidem) is a hypnotic, Tritace (ramipril) is the ACE inhibitor and Xatral (alfuzosine HCl) is an alpha-1 adrenergic blocker indicated for benign prostatic hyperplasia.